Articles tagged with Drug Targets
A team of researchers from Kyoto University found that the pituitary vasopressin system is crucial for building a robust circadian clock in the suprachiasmatic nucleus. This discovery has led to the development of potential treatments for jet lag, which currently target only the suprachiasmatic nucleus.
Researchers at University of California - San Francisco find that sense of taste signals brain to slow down eating. Using advanced techniques, they recorded brain activity in awake mice and found PRLH neurons controlled by mouth signals when eating normally, not gut signals as previously thought.
A new study at the University of Turku discovered that plixorafenib inhibits multiple signaling pathways in cutaneous squamous cell carcinoma, showing promise for treatment. The drug was originally developed for melanoma and lung cancer, but its effectiveness against cSCC is significant.
A team of researchers at Weill Cornell Medicine used an AI-based approach to uncover patterns among social determinants of health and their impact on children's health outcomes. The analysis found statistical associations between four broad patterns in social determinants and outcomes relating to child developmental health.
Researchers have identified a potential treatment for lower back pain by targeting senescent osteoclasts in the vertebral column of mice. Using anti-senescent drugs like Navitoclax may relieve spinal sensitivity and reduce pain, according to the study published in eLife.
A new study by Cleveland Clinic researchers reveals significant differences in cell communication between breast tissue with and without BRCA1/2 gene mutations. This discovery provides a foundation for personalized medicine approaches to prevent and treat breast cancer in mutation carriers.
A new resorbable scaffold has been shown to be more effective than traditional angioplasty in treating severe artery blockages in the lower leg. In a large clinical trial, patients who received the scaffold had a 74% chance of avoiding adverse events, compared to 44% for those who underwent angioplasty.
A three-year intensive treatment strategy to lower systolic blood pressure below 120mmHg significantly reduced cardiovascular events, including heart attack, stroke, and death, compared to standard treatment. The study found that participants in the intensive group experienced fewer major vascular events and deaths over a two-year period.
A new therapeutic, lepodisiran, has shown promising results in reducing lipoprotein(a) levels to undetectable levels for nearly one year. The study found that the medication is safe and effective in lowering Lp(a) levels by more than 94%.
A new anti-clotting medication, abelacimab, has significantly reduced bleeding among people with atrial fibrillation who are at risk of stroke. The AZALEA-TIMI 71 trial found that abelacimab substantially reduced bleeding compared to the current standard of care use of direct-acting oral anticoagulants.
A four-year blood-pressure intervention significantly reduced the risk of developing dementia among adults with high blood pressure, compared to those who received usual care. The study found that lowering systolic blood pressure to less than 130 mm Hg and diastolic blood pressure to less than 80 mm Hg reduced dementia risk.
A single infusion of CRISPR-based gene-editing therapy significantly reduced LDL cholesterol levels in people with heterozygous familial hypercholesterolemia, a condition that increases heart attack risk. The treatment has shown potential as a long-term or permanent option for high LDL-C control.
Researchers discovered narrow-spectrum Wnt signaling inhibitors can suppress breast cancer tumors and reduce chemo-resistant cells in mice. The treatment, derived from a bacterial toxin, targets specific receptors to minimize bone density side effects.
The C-Path Neuroscience Annual Workshop brought together stakeholders to chart a transformative course for neurology research and drug development, focusing on chronic progressive diseases such as Alzheimer's and Parkinson's. Key highlights included recommendations for innovative therapies and tools to address complex disorders.
A recent study found that transmucosal dose of buprenorphine followed by extended-release buprenorphine injection significantly reduced Clinical Opioid Withdrawal Scale scores in individuals using fentanyl. This rapid treatment strategy may be an important potential option for addressing the growing opioid crisis.
A study published in Nature Communications reveals that the 'salience network' in the brain is uniquely activated by intravenous drug use, which may be associated with higher addiction rates and faster relief from withdrawal. This finding could lead to the development of new therapies for substance use disorders.
Researchers at Texas A&M University have found a correlation between flavonoid compounds and reduced endometriosis symptoms. Flavonoids like Quercetin and Kaempferol show promise in easing inflammation, with studies suggesting they may help suppress the symptoms of inflammatory diseases like endometriosis.
The American Gastroenterological Association suggests a balanced approach when treating patients on GLP-1 RAs undergoing endoscopic procedures. AGA recommends proceeding with the procedure as planned for patients who followed standard pre-procedure fasting instructions and do not have symptoms suggesting retained gastric contents.
Scientists have created a method to keep targeted particles cool, allowing safe trapping of living cells in their native fluids. This advancement could help overcome problems with current laser light tweezers and enable targeted drug delivery applications.
Research identifies specific gut bacteria that increase risk of severe malaria in humans and mice, sparking new approaches targeting gut microbiota. The study's findings could lead to prevention strategies for severe malaria-related deaths.
A new study finds that certain gut-dwelling fungi amplify excessive inflammation in severe COVID-19 and cause long-lasting changes in the immune system. Patients with these fungi may benefit from specialized treatments targeting the fungi or immunological changes they instigate.
A study led by UC San Francisco found that homeless individuals have a 7 times higher rate of sudden cardiac death compared to the general population. Non-cardiac causes, such as overdoses and unrecognized infections, are more common among homeless people.
A new neighborhood-based care model has been shown to be effective in treating hepatitis C among injection drug users and those experiencing homelessness. The study found that 92% of participants had undetectable levels of the virus after treatment, with 84% achieving sustained virologic response.
Researchers at Hokkaido University identified 2-thiouridine as a broad-spectrum antiviral drug candidate targeting ssRNA+ viruses. It inhibits viral replication and increases survival rates in mice models for dengue and COVID-19.
Researchers are testing a single target to weaken tumors and strengthen immune cells in pediatric brain tumor patients. The goal is to improve the effectiveness of CAR-T therapy, which has shown promise but also leads to exhaustion of immune cells.
Researchers discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy. Cancer cells respond to radiation by rewiring metabolic signaling pathways using lactic acid instead of glucose.
Researchers at H. Lee Moffitt Cancer Center & Research Institute demonstrate lorlatinib's activity against protein PYK2 in non-small cell lung cancer cells, revealing a potential path for repurposing the drug for other cancers. The study shows that combination therapy targeting ROS1, PYK2, and SRC results in enhanced cancer cell death ...
Researchers at UCSF found a feedback loop between immune protein IL-31 and nerve cells, which dials back nearby inflammation and promotes skin healing. This discovery could lead to new treatments for conditions like eczema, allergies, and asthma by targeting the nervous system's role in regulating the immune response.
Researchers at Queen Mary University of London developed a new organ-on-a-chip model of the human synovium to study arthritis mechanisms and develop new treatments. The three-dimensional microfluidic device successfully replicates key features of native synovium biology.
Researchers identified YB-1 as an attractive therapeutic target for pleural mesothelioma, a cancer caused by asbestos exposure. Indirect targeting of YB-1 via histone deacetylase inhibitors showed promise in enhancing chemo- and radiotherapy sensitivity.
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
Researchers discovered the STAT3 signaling pathway as a potential target for treating H3K27M-mutant diffuse midline gliomas (DMGs), a uniformly lethal central nervous system malignancy. The current standard of care, including palliative radiation and chemotherapy, remains ineffective in this disease.
Researchers at the University of Virginia Health System are developing computer models to better understand the cellular processes and gene activity of multi-drug resistant bacteria Staphylococcus aureus and Pseudomonas aeruginosa. The goal is to identify vulnerabilities in these bacteria and advance the development of new treatments.
A study of over 850,000 Australian children born between 2009 and 2017 found a small increased risk of birth defects among those conceived through fertility treatment, partly attributed to parental infertility. The use of intracytoplasmic sperm injection (ICSI) was also associated with an increased risk for genitourinary abnormalities.
A study found that people with a specific genetic mutation in the CARD9 gene have higher IL-17 protein levels, making them more responsive to IL-17 inhibitor biologics. This discovery may lead to targeted treatment recommendations for ankylosing spondylitis patients.
A new study examines cannabis use patterns, motivations, and risk factors among college students at a large public university in the southeastern US. The researchers found that top reasons for cannabis use were relaxation and social pressure, while daily users reported higher quantity of cannabis per day.
A new national ALS research consortium, Access for All in ALS, has been launched with a $16.7 million NIH award. The consortium will include 34 clinical sites nationwide and generate a longitudinal biorepository linked to detailed clinical information.
Brazilian researchers screened 160 existing drugs and identified six compounds effective against Toxoplasma gondii. Almitrine, a COPD treatment, showed significant reduction in brain parasite load. Further studies are needed to repurpose these drugs for toxoplasmosis treatment.
A real-world study confirms the reliability and effectiveness of the Pooled Cohort Equation (PCE) in assessing cardiovascular risk, regardless of statin use. The PCE performed well across different demographics and retained accuracy with measurement factors outside its original risk profile range.
A new drug called vorasidenib has been shown to significantly slow tumor growth and extend the average time until tumor growth in patients with grade 2 IDH-mutant gliomas. This breakthrough could offer a first early treatment option for these cancer patients, potentially improving their quality of life.
Researchers found that etripamil nasal spray restored normal heart rhythms within 30 minutes in 54% of patients, making it a potential new option for self-treating paroxysmal supraventricular tachycardia. The study showed the medication to be safe and well-tolerated.
Veterinary researchers used 3D organoids to investigate lung cancer in dogs, finding that canine primary lung cancer organoids faithfully mirrored tumor tissues. The study identified correlations between organoid cell viability and specific target molecules, paving the way for personalized treatment approaches.
Researchers found that adding dendritic cell boosting therapy to radiation and CTLA4 inhibitor combination produced synergistic effect, eliciting tumor regression. This approach resulted in complete or almost complete elimination of targeted tumors.
Researchers at St. Jude Children's Research Hospital refined the definition of hyperdiploidy in childhood B-cell acute lymphoblastic leukemia (B-ALL), using DNA index to predict patient outcomes. The study found that a simpler system captures a significant proportion of patients with excellent prognoses, and that individual chromosome ...
Researchers found that DPP4 inhibition increased sunitinib efficacy in RCC spheroids and upregulated DPP4 in sunitinib-resistant cells. This suggests potential repurposing of DPP4 inhibitors to target therapy resistance in renal cell carcinoma.
A new Northwestern Medicine study reveals that a dysfunction in the neuron's synapses leads to deficits in dopamine and precedes neurodegeneration in Parkinson's disease. The findings suggest targeting dysfunctional synapses before neurons degenerate may represent a better therapeutic strategy.
Philip Low, a Purdue University researcher, is working on validating a previously successful malaria treatment by reducing the number of days required for therapy. His goal is to prevent drug-resistant strains from proliferating and save lives in developing countries.
A recent study from MIT found that measuring diversity of mutations within a tumor generates more accurate predictions of treatment success than overall mutation count. This discovery could help doctors identify patients who would benefit most from checkpoint blockade inhibitors.
Researchers discuss new drugs available for HER2-positive breast cancer patients with brain metastasis, showing improved outcomes and quality of life. The development of targeted therapies has led to better survival rates among these patients.
A new study suggests that transcranial ultrasound stimulation can be used to change specific types of activity within the brain, paving the way for targeted treatments of mental health conditions. The research found that TUS induced significant changes in GABA concentration and altered communication between brain regions.
Researchers found that a combination of AXL and EGFR inhibitors can suppress tumor growth and prevent relapse in patients with certain cancers. The study clarifies the novel regulatory mechanism by which AXL stimulates YAP via the EGFR-LATS1/2 axis.
A randomized trial published in The Lancet Oncology found that condensing prostate beam scanning proton therapy for breast cancer patients can result in similar control of the cancer while sparing surrounding normal tissue. The study demonstrated excellent outcomes, with reduced skin side effects and comparable complication rates.
Researchers at University of Tsukuba found that aripiprazole modulates the mammalian central circadian clock by disrupting synchronization among clock neurons and enhancing responsiveness to light stimuli in mice. This discovery expands the potential clinical usage of aripiprazole as a treatment for circadian rhythm sleep disorders.
Researchers are developing a new treatment for ischemic stroke by targeting the prostaglandin receptor EP2, which could have a wider therapeutic window and improve behavioral outcomes. The potential new treatment has the potential to reduce inflammation and provide protection for neurons after an ischemic stroke.
Chung-Ang University researchers create an electrochemical DNA biosensor that detects HPV-16 and HPV-18 with high specificity, facilitating early diagnosis of cervical cancer. The sensor uses a graphitic nano-onion/MoS2 nanosheet composite to enhance conductivity.
Research found that cold weather slightly increases blood pressure and decreases blood pressure control rates during winter months. Participants' systolic blood pressure increased by up to 1.7 mm Hg in the winter months compared to summer, while blood pressure control rates decreased by up to 5%.
Researchers discovered that immune cells create local gradients by consuming chemokines, guiding their movement and enhancing directional movement in complex environments. This finding increases understanding of coordinated immune responses and may reveal new strategies for targeting cancer
Researchers developed a new formulation of doxorubicin that targets cancer cells while reducing cardiotoxicity. The protein-shell encapsulation increases specificity for cancer cells and decreases harm to healthy heart cells.
Mayo Clinic researchers found that cells expressing PD-1 and PD-L1 within a certain distance of each other can predict the success of immunotherapy in patients with colorectal cancer. This spatial analysis may help select patients most likely to benefit from treatment, improving outcomes and minimizing unnecessary treatments.
A new study found that antibiotics promote the growth of antibiotic-resistant bacteria in the gut by providing extra nutrients, allowing these 'bad' bacteria to multiply. The research suggests that targeting beneficial bacteria can help restrict the growth of resistant bacteria, paving the way for microbiome therapeutics treatments.